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ABSTRACT
Background: The aim of this study was to compare the efficacy of metabolic control and levels 
of interleukin 6 (IL‑6) in gingival crevicular fluid after periodontal therapy in type 2 diabetes 
mellitus (DM) and nondiabetic (NDM) patients.  
Methods: This study was performed in 20 subjects (10 type 2 DM and 10 NDM patients with 
generalized chronic periodontal disease. Both groups were recorded for clinical parameters 
(plaque index (PI), gingival index (GI), probing depth (PD), gingival recession (GR) and clinical 
attachment level (CAL)), metabolic control (fasting glucose levels, glycated a‑hemoglobin 
(HbA1c), low‑density lipoprotein (LDL), high‑density lipoprotein (HDL), triglycerides (TR)), 
and IL‑6 levels at baseline and 3 months after periodontal treatment. 
Results: DM and NDM patients revealed significant statistical reductions for clinical parameters 
(P < 0.05, RM ANOVA) after 3 months. DM group had improvements on HbA1c and had 
significant statistical increased of TRG (P < 0.05, RM ANOVA) after 3 months. No differences 
of LDL/HDL and IL‑6 levels were found after 3 months in both groups. 
Conclusion: DM group presented a significant reduction of HbA1c levels after periodontal 
therapy. However, TRG levels increased after 3 months, which suggest more confirmatory 
studies to investigate if these results will be repeated in other studies.  
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of National Health and Nutrition Survey (NHANES) III 
confirm the increase in periodontitis prevalence among 
diabetics.[4] Longitudinal Pima Indian Population studies 
showed enhance in the prevalence of attachment and bone 
loss after periodontal exams in poor metabolic control.[5] 
The relationship between glycemia control of diabetes and 
periodontal disease is unclear due to some uncontrolled 
diabetic patients may develop extensive periodontal 
destruction or not, as well as, controlled diabetic patient 
can have an excellent periodontal healthy or may develop 
periodontitis.[6] 
Several studies have been reported potential mechanisms 
involving interactions with periodontitis, diabetes, metabolic 
control, tissue repair, and immune cell function. [7,8] 
Periodontal destruction observed in periodontitis is host‑
mediated through release of proinflammatory cytokines by 
local immune cells in response to bacterial flora and products/
metabolites, especially lipopolysaccharide (LPS). [9,10] 
Tumoral necrosis factor alpha (TNF‑α) and interleukin 
1 beta (IL‑1β) are significantly elevated in periodontal disease 
sites and demonstrates inflammation during periods of active 
disease and tissue destruction.[11] TNF‑α is a major signal 
for cellular apoptosis, bone resorption, methaloproteinase 
(MMP) secretion, intercellular adhesion molecule (ICAM) 
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Diabetes mellitus (DM) is a metabolic disorder and has 
been considered a risk factor for periodontal disease. DM 
has two major forms, type 1 and 2, which have distinct 
etiology. Type 1 diabetes occurs when autoimmune‑induced 
inflammation provokes destruction and apoptosis of beta 
cells pancreas leading to insufficient insulin production. 
Type 2 is characterized as an alteration of insulin production 
and it is almost found in obese people or patients with an 
increase percentage of body fat in the abdominal region.[1,2] 
The presence of diabetes increases the prevalence, incidence 
and severity of periodontitis.[3] Epidemiological studies 
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expression, and IL‑6 production. IL‑6, once produced, 
stimulates osteoclast activation, thus, bone resorption, 
and facilitates T‑cell differentiation.[12] Pro‑inflammatory 
cytokines, interleukin‑1 (IL‑1) and TNF‑α are elevated in 
the gingival crevicular fluid or serum of diabetic patients, and 
they were correlated with periodontal tissue destruction.[13] 
Based on theses facts, the aim of this study was to evaluate if 
DM type 2 and NDM patients, both with chronic periodontal 
disease, would present changes between groups and timing 
evaluations, at baseline and in 3 months follow‑up, in 
periodontal status, metabolic control and interleukin 6 (IL‑6) 
levels in the gingival crevicular fluid after periodontal 
therapy.
MATERIALS AND METHODS
A total of 20 patients (30‑65 years old) from Graduate 
Clinic with clinical diagnosis of generalized chronic 
periodontitis defined by probing depth >5 mm at least in 
10 teeth, radiographic bone loss ranging from 30% to 50% 
and presence of at least 20 teeth per mouth, were included. 
Exclusion criteria were: Use of antibiotics during the 
previous 6 months, pregnancy, smoking, other systemic 
diseases, use of immune suppressive medication, phenytoin, 
cyclosporine, calcium channel blockers or any medication 
that could interfere in the periodontium or in response to 
periodontal therapy.
To compute required sample size the standard deviation 
was estimated from study Da Cruz et al.[14] that considered 
means and standard deviations of sites with probing depth 
>5 mm for diabetes mellitus groups (DM) (33.60 ± 15.70), 
and nondiabetes mellitus group (NDM) (20.1 ± 7.24),  using 
G*Power (Version 3.1.2, Franz Faul, Universität Kuel, 
Germany, 1992‑2009) based on t‑test means difference 
between two independent means, considering  α = 0.07 and 
power of  0.80, respectively, so we have obtained a sample 
size equal to 10 patients.
The selected patients were divided into two groups: An 
experimental group of 10 patients diagnosed with type 2 DM 
(medication supplementation attested by an endocrinologist) 
and 10 NDM. Diabetic patients informed the diabetes 
diagnosis duration (in years) and their daily consumption of 
medication. The patients were evaluated for 3 months, from 
August to November 2008. This research was conduced after 
approving by the Ethical Committee of Research. 
Blood samples were taken at baseline and at 3‑month 
recall visit. Fasting glucose levels, glycated a‑hemoglobin 
(HbA1c), low‑density lipoprotein (LDL), height‑density 
lipoprotein (HDL), and triglycerides (TR), were evaluated 
in all patients. Clinical parameters were also measured at 
baseline and 3 months after therapy.  Probing depth (PD), 
gingival recession (GR), clinical attachment level (CAL), 
plaque index (PI), and gingival index (GI)[15] were measured 
by a single examiner with a PCP (PCP‑UNC15, Hu‑Friedy, 
Chicago, IL) periodontal probe at four sites per tooth at all 
teeth, excluding third molars.
After clinical measurements, the supragingival biofilm was 
removed with sterile gauze. Gingival crevicular samples 
were taken from two sites with the deepest PD (≥5 mm) 
in each patient using a sterile paperpoint from the deepest 
pocket for 30 s. Gingival crevicular fluids were inserted in 
two eppendorf tubes containing phosphate buffer saline 
and were stored at -80°C. The samples were collected in 
the same site at baseline and 3 months post‑therapy and 
were analyzed by ELISA (enzyme‑linked immunosorbent 
assay) using commercial kits (R&D Systems, Minneapolis, 
MN, USA). 
After removing baseline samples of biofilm, full‑mouth 
scaling and root planning (SRP), under local anesthesia, 
was performed in all sites with periodontal disease in 
a single session. Oral hygiene instructions for home 
care procedures (tooth brushing technique, interdental 
cleaning and use of tongue scrapers) were given by an 
experienced periodontist. The maintenance therapy 
included professional plaque control at 2 weeks interval 
during the 3 months of the study.
Statistical analysis 
Statistical tests were accomplished using the SAS software 
(Institute Inc., Cary, NC, USA, Version 9.1, 2003). Repeated 
measures analysis of variance (RM ANOVA) was performed 
to compare clinical parameters (PI, GI, PD, GR, and AL) 
and metabolic parameters (fasting glucose, HbA1c, LDL, 
HDL, TRG) between both time intervals and DM and 
NDM groups. All variables were normally distributed, 
except IL‑6. The Mann‑Whitney test was used to analyze 
differences in IL‑6 levels between baseline and at 3‑month 
recall. Statistical significance for all variables was defined 
at the 5% level.
RESULTS
Periodontal results
Descriptive statistics with means and standard deviations of 
the variables are presented in Table 1. Statistically significant 
differences were observed for age between DM and NDM 
groups (paired t‑test (P = 0.002). Regarding the distribution 
of sites, mean number of observed sites present in DM group 
was higher than NDM group. Mean number of sites with 
periodontal disease (with PD > 5 mm) were also highest in 
DM group. 
Presence of plaque was evaluated on all tooth surfaces 
[Table 2]. Plaque index (PI) were determined for the whole 
mouth (%) in both DM and NDM groups at different time 
intervals (DM and NDM; P=0.0301; baseline and 3 months 
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P = 0.0184; RM ANOVA). DM group exhibit more numbers 
of sites with plaque at the initial of treatment than NDM 
group. Significant reduction of plaque was found in DM 
and NDM groups after 3 months. Gingival index (GI) was 
evaluated on all tooth surfaces [Table 2]. Gingival index 
was determined for the whole mouth (%) in both DM and 
NDM groups in different time intervals (DM and NDM; 
P = 0.3034; baseline and 3 months; P = 0.0015; RM ANOVA). 
No significant difference was found between DM and NDM 
groups, but statistically significant reduction of bleeding 
on probing after 3 months. Both groups demonstrated 
reduced plaque and bleeding on probing after 3 months and 
improvement in oral hygiene. Based on PI and GI changes, 
the response to the oral hygiene procedures was similar for 
the two groups.
Table 3 summarizes probing depth, gingival recession, and 
attachment level. The probing depth had no statistically 
significant difference between groups DM and NDM and 
between time intervals (DM and NDM; P = 0.0199; baseline 
and 3 months; P = 0.001; RM ANOVA). No differences were 
found for gingival recession between DM and NDM groups 
at baseline and after 3 months (DM and NDM; P = 0.1858; 
baseline and 3 months; P = 0.7486; RM ANOVA). Clinical 
attachment levels had no statistically differences between 
groups DM and NDM between the different time intervals 
(DM and NDM; P = 0.6958; baseline and 3 months; 
P = 0.4486; RM ANOVA).
Metabolic analysis
Metabolic control was expressed by means of fasting 
glucose level, HbA1c, LDL, HDL, TRG. The fasting glucose 
levels showed significant differences between DM and 
NDM groups at baseline (P = 0.0034; RM ANOVA), but no 
significant statistically differences between the baseline 
and 3 months (P = 0.9426; RM ANOVA) [Figure 1]. The 
HbA1c had significant statistically difference between 
NDM and DM groups at baseline (P = 0.0108; RM ANOVA) 
and significant statistically reduction between the baseline 
and 3 months after periodontal treatment (P = 0.040 
RM ANOVA) [Figure 2]. The LDL showed significant 
statistically difference between DM and NDM group at 
baseline (P = 0.0265; RM ANOVA), but no significant 
statistically difference after 3 months (P = 0.6289; RM 
ANOVA) [Figure 3]. The HDL presented no significant 
statistically difference between DM and NDM groups 
and between baseline and 3‑month recall (P=0.9471; RM 
ANOVA; P = 0.1098; RM ANOVA) [Figure 4]. The TRG 
showed significant statistically difference between DM 
and NDM groups and between baseline and 3 months 
(P = 0.0488; RM ANOVA; P = 0.0571; RM ANOVA) 
[Figure 5].
Modulation of IL-6 production of gingival fluid
Modulation of IL‑6 production in gingival crevicular fluid 
was presented on Figure 6. No statistically significant 
Table 1: Subjects characteristics (mean±S.D.) at baseline




Age (years) 52±8.72* 41.6±7.55
Total sites (N) 71.6±21.37 94.4±15.8
Sites with PD>5 mm 16.2±12.02 12.5±5.97
Diabetes duration (years) 6.6±4.17 NA
Medicine consumption (mg/dia) 1445±806.38 NA
*Statistically significant difference between groups for age (Student test; 
P<0.05). NA=Not applicable, DM=Diabetes mellitus, NDM=Nondiabetic 
mellitus
Table 2: PI and GI values (mean±S.D.) for DM and NDM 
group at baseline and 3 months















*Statistically significant differences (P<0.05) were noted in PI between DM 
and NDM groups. †Statistically significant reduction (P<0.05) were noted to 
PI and GI between baseline and 3 months values to DM and NDM groups 
DM=Diabetes mellitus, NDM=Nondiabetic mellitus, PI=Plaque index, 
GI=Gingival index
Table 3: Whole‑mouth clinical indices (mean± S.D.)






























*Statistically significant differences (P<0.05) were noted between DM and 
NDM groups for PD. †Statistically significant differences (P<0.05) between 
baseline and 3 months values to DM and NDM groups for PD and CAL 
DM=Diabetes mellitus, NDM=Nondiabetic mellitus, GR=Gingival recession, 
CAL= Clinical attachment level, PD=Probing depth 
differences for IL‑6 levels (P < 0.05) were detected between 
DM and NDM groups at baseline and 3 months follow‑up 
(Mann‑Whitney test). Nevertheless, the number of sites 
detected with IL‑6 was reduced. At the beginning of study, 
40% and 45% of sites presented IL‑6 in NDM and DM 
groups, respectively, but only 20% of the sites presented 
this interleukin at the final exam in both groups.
DISCUSSION
In the present study, DM and NDM groups with generalized 
chronic periodontal disease were selected and treated by full 
mouth scaling and root planning to verify whether there 
were changes in metabolic control, periodontal status, and 
IL‑6 levels between DM and NDM groups and  baseline and 
3 months after periodontal therapy. Periodontal status and 
IL‑6 levels reveal similar responses after periodontal therapy 
in both groups. Improvements of Hba1c and increased of 
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Figure 1: Mean values and standard deviations of fasting glucose 
level (mg/dl) for DM and NDM patients at baseline and 3 months after 
full‑mouth scaling and root planning. *Statistically significant reductions 
(P<0.05) were detected between DM and NDM
 %DVHOLQH+E$FPJGO 1'0'0  PRQWKV
Figure 2: Mean values and standard deviations of glycated 
a‑hemoglobin (HbA1c mg/dl) for DM and NDM group at baseline 
and 3 months after full‑mouth scaling root planning. *Statistically 
significant differences to HbA1c (P<0.05) were detected between DM. 
†Statistically significant reductions to HbA1c (P<0.05) were detected 
between baseline and 3 months to DM and NDM %DVHOLQH/'/PJGO 1'0'0PRQWKV
Figure 3: Mean values and standard deviations of low‑density 
lipoprotein (LDL mg/dl) for DM and NDM group at baseline and 
3 months after full‑mouth scaling root planning. *Statistically significant 
differences to LDL (P<0.05) were detected between DM and NDM
 %DVHOLQH+'/PJGO 1'0'0PRQWKV
Figure 4: Mean values and standard deviations of high‑density 
lipoprotein (HDL mg/dl) for DM and NDM group at baseline and 3 
months after full‑mouth scaling root planning
Figure 6: Medium of interleukin 6 (IL‑ 6) cytokine production of gingival 
crevicular fluid for DM and NDM group at baseline and 3 months after 
full‑mouth scaling root planning. No Statistically significant differences 
to IL‑6 (P<0.05) were detected between DM and NDM and baseline 
and 3 months (Mann‑Whitney test)
 %DVHOLQH75*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Figure 5: Mean values and standard deviations of triglycerides 
(TRG mg/ dl) for DM and NDM group at baseline and 3 months after full‑
mouth scaling root planning. †Statistically significant increased to TRG 
(P<0.05) were detected between baseline and 3 months to DM and NDM
LDL were found in DM group after 3 months after full‑
mouth scaling and root planning.  
Ternoven and Oliver[16] evaluated the long‑term control of 
diabetes and periodontitis and reported that uncontrolled 
diabetes patients should present more calculus and 
extensive periodontal pocket. According to these 
observations in the initial exam of this study, found at 
baseline, more number of sites with periodontal disease, 
height PI and GI almost 83% and 61%, respectively, and 
attachment loss to DM group, uncontrolled diabetes 
type 2, when compared NDM group, Tables 1‑3, 
respectively. However, no differences were found to PD, 
GR, CAL between DM and NDM groups, but statistically 
significant reductions of clinical parameters were found 
after 3 months. 
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The benefit of periodontal therapy by full‑mouth scaling 
and root planning in a single session was previously 
reported by Da Cruz et al.,[14] which also showed significant 
reductions in clinical parameters when treated for DM type 
1 group. Although no effect on the glycemia control was 
observed. However, in this study the same methodological 
aspect were repeated in type 2 diabetes patients and 
improvements of HbA1c were found. These results suggest 
that type 1 diabetes should have other variables involved 
in the control of diabetes than type 2 diabetes. Additional 
advantages were reported by Da Cruz et al.[14] in the aspects 
of advantage of full mouth root planning when compared 
with the conventional therapy, it was effective to reduce 
the number of scaling sessions, i.e., the bacterial plaque and 
calculus removal occur in just one appointment and when 
it is associated  with a rigorous oral hygiene control the 
periodontal clinical results can be maintained. 
Controversies about the influence of periodontal 
treatment in metabolic control have been discussed.[3,6,7] 
Herring and Shah,[17] Taylor[18] and Mealey and Oates,[19] 
reported improvements on glycemia control occur due 
to the reduction of tissue inflammation after periodontal 
treatment. Rodrigues et al.[20] Kiran et al.[21] Faria‑Almeida 
et al.[22] and Schara et al.[23] reported statistically significant 
reduction of HbA1c after 3 or 6 months periodontal 
treatment in diabetic patients. However, Kawamura 
et al.[24] Al‑Mubarak et al.,[25] and Da Cruz et al.[14] did not 
find significant differences to glycemia control in DM group 
after the periodontal treatment. In this study, at the initial 
exam were selected uncontrolled diabetics type 2 and after 
3 months the periodontal treatment, alone, was capable 
of improving metabolic control by analysis of HbA1c, 
Figure 2, although fasting glucose levels did not changes, 
Figure 1. Soskolne and Klinger[8] suggest that a meticulous 
control of the hyperglycemia is necessary to consider the 
levels of glycated serum proteins, especially HbA1c which 
because its incorporation in to the red blood cells, gives an 
indication of the serum glucose levels over the proceeding 
2‑3 months. 
Other metabolic parameters evaluated in this study are 
the levels of LDL, HDL, and TRG. The levels of LDL/HDL 
did not change between initial and 3 months after the 
periodontal therapy. Even though, the levels of LDL were 
high to DM group than NDM at baseline. The levels of TRG 
were high at the beginning of the study and increased after 
3 months of periodontal therapy to DM group. According 
to these results, Iacopino,[6] suggests that diabetes type 
2 patients are prone to elevated LDL/TRG, because of 
diabetes and hyperlipidemia is often accompanied. Recent 
studies suggest that local chronic and acute systemic 
infections have to induce profound changes in plasma 
cytokines and hormones, leading to a catabolic state altered 
lipid metabolism.[6,26] Herzberg et al.,[27] Colombo et al.,[28] 
Haraszthy et al.,[29] reported that a localized oral infection 
such as periodontitis, can lead to generalized alterations in 
lipid metabolism. 
In periodontitis, proinflammatory cytokines IL‑1β, TNF‑α, 
and IL‑6 are produced in response to plaque bacteria. IL‑1β, 
TNF‑α, IL‑6 are mediators of tissue destruction that induce 
degradation of connective tissue and resorption of alveolar 
bone.[30] Persistent elevations of  IL‑1β, TNF‑α, and IL‑6 in 
the diabetic state have an effect on the liver and stimulate 
the realization of acute‑phase proteins, produce the 
dysregulation of lipid metabolism associated with diabetes 
type 2 and have effect on the pancreatic beta cells.[31]
The volume of cytokine in the GCF is proportional to the 
degree of tissue inflammation and can be reduced after 
periodontal treatment.[32] Navarro‑Sanchez et al.[33] reported 
the results of the efficacy of nonsurgical periodontal therapy 
between type 2 diabetes mellitus and nondiabetes patients 
above periodontal status, glycemia control and levels of 
IL‑1β and TNF‑α. The author found similar response to 
both group DM and NDM, and improvements in glycemia 
control. The results of the authors suggest that there were 
no differences found between groups DM and NDM, and 
baseline and 3 months after the periodontal therapy. To 
levels of IL‑1β and TNF‑α,  significant reduction were 
reported after 3 and 6 months evaluations, although no 
differences were found between groups DM and NDM. 
In the present study the IL‑6 levels in the GCF were 
analyzed, and no differences were found between initial 
and final exams and between DM and NDM group after 
full mouth root planning. Mengel et al.[34] and Buhlin 
et al. [35] reported that periodontitis has been associated with 
increased circulating levels of IL‑6. This increase appears 
to be correlated with disease severity.[35] Furthermore, 
D’Aiuto et al.[36] reveals that periodontal treatment can 
decrease inflammatory mediators due to inflammation 
control. Forner et al.[37] evaluated the level of IL‑6 after 
scaling and root planning and concluded that after 8 h 
the plasma concentration had increased. These results 
supported the presence of bacteremia after periodontal 
procedures. Adriankaja et al.[38] evaluated the levels of IL‑6 in 
725 subjects, NDM and DM type 2 with periodontal healthy 
or gingivitis and concluded that high levels of IL‑6 were 
detected in DM group when biofilm was presented.  Patricia 
et al.[39] found significantly reduced IL‑6 serum levels (by 
48%) following the significant improvements in the clinical 
(PD, CAL, and BOP) and metabolic (HbA1c) measurements 
after periodontal therapy associated to doxycycline in 
diabetic type 2 patients after 3 months. The authors suggest 
that reductions of IL‑6 levels were accompanied with the 
reductions of HbA1c. However, Talbert et al.[40] investigated 
if scaling and root planning (SRP) could reduce IL‑6 levels 
and TNF‑α in diabetes type 2 population after 3 months 
and concluded that an increase in IL‑6 levels and TNF‑α 
could be found followed by SRP, but this result was not 
Periodontal therapy in type 2 diabetes mellitus Camargo, et al. 
Indian Journal of Dental Research, 24(1), 2013115
statistically significant and they did not show the hypothesis 
of reduction agreement with the results of this study.
The findings of the present study should be considered with 
caution due to the relatively small sample size, however, this 
study was based on statistical analysis of clinical parameter 
relevance that calculated small differences between means of 
groups of 4% for PI (power analysis PI 4% = 0.9289), 4% for GI 
(power analysis GI 4% = 0.8199), 1 mm for PD (power analysis 
PD = 0.8749), 1 mm for GR (power analysis GR = 0.9989), and 
1 mm for CAL (power analysis CAL = 0.9020), considering 5% 
of type I error (α = 0.05). The power analyses were calculated 
based on means and standard deviations of control groups 
and the minimum power were 0.81 (b = 0.19) for all clinical 
parameters.  Otherwise, no other published study has carried 
out similar analysis in diabetic patients submitted to scaling 
and root planning therapy in a single session.
CONCLUSION
Within the limits of this study, it can be concluded that 
periodontal therapy was effective to control the periodontal 
disease. Significant improvement of periodontal status was 
found in both groups DM and NDM after 3 months, but 
no significant changes were found between DM and NDM 
groups for gain of attachments. The metabolic control 
presented reduction of HbA1c to DM group after periodontal 
treatment and it is in accordance to the literature. However, 
LDL levels were still high and the TRG was increased in 
DM group after 3 months periodontal treatment. Therefore, 
confirmatory studies are needed to verify if LDL/TRG levels 
could be maintained for long‑term evaluations.
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